Prosecution Insights
Last updated: April 19, 2026

Examiner: WARD, PAUL V

Tech Center 1600 • Art Units: 1622 1624

This examiner grants 83% of resolved cases

Performance Statistics

83.2%
Allow Rate
+23.2% vs TC avg
1708
Total Applications
-11.0%
Interview Lift
942
Avg Prosecution Days
Based on 1672 resolved cases, 2023–2026

Rejection Statute Breakdown

2.1%
§101 Eligibility
19.4%
§102 Novelty
19.1%
§103 Obviousness
43.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18394928 CRYSTALLINE FORMS OF A LPA1 ANTAGONIST Non-Final OA Bristol-Myers Squibb Company
18446244 INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION Non-Final OA The Johns Hopkins University
18002636 HAIR CARE COMPOSITION Non-Final OA Conopco, Inc., d/b/a UNILEVER
17794109 METHOD FOR TREATMENT OF ACQUIRED COGNITIVE DEFICITS Non-Final OA CORNELL UNIVERSITY
18052505 LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS Non-Final OA Arcturus Therapeutics, Inc.
17904039 POLYACRYLATE-FREE COSMETIC PREPARATION Non-Final OA BEIERSDORF AG
17997056 COMPOSITION FOR REDUCING HEPATIC TRIGLYCERIDES AND/OR IMPROVING GLUCOSE METABOLISM Non-Final OA Universite Laval
18574167 CANNABIDIOLIC ACID ESTERS FOR TREATING PRADER-WILLI SYNDROME Non-Final OA Yissum Res Dev Co of Hebrew Uni of Jerusalem Ltd.
17966782 COMPOSITIONS OF BERBERINE URSODEOXYCHOLATE AND METHODS THEREOF FOR TREATING FATTY LIVER DISEASE, DIABETES AND HYPERLIPIDEMIA Non-Final OA SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD.
18024623 RHO KINASE INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION Non-Final OA The Schepens Eye Research Institute, Inc.
18209437 PYRROLINONE COMPOUND AND METHOD FOR PREPARING THE SAME Non-Final OA WUHAN JIANMIN DAPENG PHARMACEUTICAL CO., LTD.
17311784 A VILAZODONE SOLID DISPERSION AND PREPARATION METHOD THEREOF Final Rejection SUNSHINE LAKE PHARMA CO., LTD.
17967344 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE Non-Final OA OLIGOMERIX INC.
17956867 APPLICATION OF ACRIDINEDIONE COMPOUND IN PREPARATION OF ANTI-DIABETIC DRUGS Non-Final OA THE FOURTH MILITARY MEDICAL UNIVERSITY
17908200 LIGHT-ACTIVATED PATHOGEN-KILLING MOLECULES AND USES THEREOF Non-Final OA EPIC VENTURES INC.
17802651 Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate and pharmaceutical compositions thereof Non-Final OA AIC246 AG & Co. KG
17759232 CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF Non-Final OA JIANGSU HENGRUI MEDICINE CO., LTD.
17866672 QUINOXALINE DERIVATIVES Non-Final OA GRUENENTHAL GMBH
17270665 NOVEL BISARYLETHER COMPOUNDS Non-Final OA XENIOPRO GmbH

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month